# Diabetes Research Hub — Monitor Report

**Run date:** 2026-06-09 (automated scheduled monitor)
**Latest underlying data:** 2026-06-07 snapshots
**Previous monitor report:** 2026-06-07

---

## TL;DR — What's Actionable

1. **Breaking (web):** The ADA 86th Scientific Sessions closed June 8 in New Orleans with Phase 3 readouts for retatrutide, orforglipron, CagriSema, and survodutide. The **retatrutide Phase 3 paper landed in *The Lancet* (PMID 42250575, Jun 6)** and is already in our PubMed snapshot — flagged as a cross-domain key-therapy hit. Worth a full read and a tracker entry.
2. **Data is 2 days stale.** No clinical-trial or PubMed snapshot exists for Jun 8 or Jun 9. The daily export scripts have not run since Jun 7. Recommend re-running `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py`.
3. **Gap matrix is 50 days old.** `literature_gap_data.json` last regenerated 2026-04-20. The interpreted report is fresh (Jun 7) but sits on stale underlying counts. Recommend re-running `project1_literature_gap_analysis.py`.

---

## File System Status

| File | Last modified | Status |
|------|---------------|--------|
| hub_monitor_report.md | 2026-06-07 | Current |
| clinical_trials_latest.json | 2026-06-07 | 2 days old |
| pubmed_recent_latest.json | 2026-06-07 | 2 days old |
| literature_gap_report.md | 2026-06-07 | Current (interpreted) |
| literature_gap_data.json | **2026-04-20** | **STALE (50 days)** |
| literature_gap_matrix.xlsx | **2026-04-20** | **STALE (50 days)** |

All five key inputs exist and were readable. No missing files. The hub monitor itself flagged 686 result files older than 14 days — most are dated daily snapshots that are expected to age out, not a concern. The one genuine staleness flag is the gap-analysis matrix.

Note: no `clinical_trials_snapshot_2026-06-08/09` or `pubmed_recent_snapshot_2026-06-08/09` were produced — the daily pipeline appears to have paused after Jun 7.

---

## Clinical Trial Changes

Total unique trials tracked: **802** (T1D cure/cell 150, T1D immuno/prevention 73, T2D novel 139, devices 221, completed-with-results 290). Status mix: 290 completed, 263 recruiting, 134 not-yet-recruiting, 108 active-not-recruiting.

**Changes since the last full snapshot diff (2026-06-02 → 2026-06-07):**

New trials (4):
- **NCT05813912** (Novo Nordisk, Phase 3, COMPLETED) — weekly insulin icodec study; results posted Jun 3.
- **NCT07619833** (Daewoong, Phase 3, not-yet-recruiting) — initial combination therapy for T2D.
- **NCT07628985** (Carnot Labs, Phase 3, not-yet-recruiting) — BALANCE-DM2, bofanglutide in T2D.
- **NCT04167761** (Stanford, Early Phase 1, COMPLETED) — ertugliflozin cardioprotective/epicardial-fat study; results posted Jun 4.

Status changes (2): NCT07472725 (not-yet → active-not-recruiting, SHR-3167); NCT07303803 (not-yet → recruiting, chiglitazar). Removed (2): NCT06853990, NCT06688123. No new results posted between the 06-02 and 06-07 snapshots (the two results above were carried in the 06-07 export).

**Key Phase 3 trials worth watching (RECRUITING):**
- **Vertex VX-880 / zimislecel** — NCT06832410 and NCT04786262, both Phase 3 recruiting (T1D cell therapy; Tier 1 relevance).
- **Eli Lilly baricitinib** — NCT07222332 (preserve beta-cell function) and NCT07222137 (delay Stage 3 T1D), both Phase 3 recruiting. Baricitinib repurposing for T1D is a notable immunotherapy signal.
- **Sanofi teplizumab** — NCT07088068, Phase 3 recruiting (head-to-head teplizumab comparison).
- **vTv cadisegliatin (glucokinase activator)** — NCT06334133, Phase 3 recruiting; aligns with our Glucokinase gap cluster.
- **Novo Nordisk insulin icodec** — NCT07076199, Phase 3 recruiting.

Of the 802 trials, 291 carry posted results; the most recent (Jun 1–4) are device, dietary, and SGLT2 studies (ertugliflozin epicardial fat, icodec, precision diets). None are Vertex/Lilly/Novo/Sana flagship readouts in the snapshot window — those came via the ADA meeting (see Breaking News).

---

## PubMed Highlights

Latest snapshot: 167 unique papers across 16 alert domains (30-day lookback). 88 papers are new versus the 2026-06-02 snapshot.

**Cross-domain papers (highest priority — 11 total):**
- **[42250575] *Lancet*, Jun 6** — "Efficacy and safety of retatrutide, a GIP/GLP-1/glucagon receptor agonist…" — domains: T2D GLP-1 New + Key Therapy retatrutide. **Top pick.**
- **[42251179] *NPJ Digital Medicine*, Jun 6** — proteomic clocks + deep learning for eye aging/disease — AI/ML + Biomarker. Relevant to Tier 1 Multi-Omics + AI/ML prediction.
- **[42251203] *Diabetologia*, Jun 6** — plasma three-miRNA signature for early beta-cell dysfunction — Biomarker + Gene Therapy. Directly relevant to Tier 1 Multi-Omics Biomarker Integration.
- [42163482] *Proteomics* — extracellular-vesicle proteins predicting T1D (T1D cure + immunotherapy + teplizumab).
- [42198313] GLP-1 in diabetes + stroke (orforglipron/retatrutide/CagriSema).
- Others span T2D remission/multi-omics, microbiome/multi-omics, and epigenetics/multi-omics intersections.

**Key-therapy mentions** tracked this cycle: zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, teplizumab, icodec, dapagliflozin (2 papers each). Standouts: the retatrutide *Lancet* paper above; a teplizumab systematic review (42221148); and a post-Tzield islet-autoantibody ordering analysis in *JCEM* (42138126).

**Volume trend:** ~167 papers/30 days, consistent with prior cycles. Microbiome, AI/ML, Biomarker, and Health Equity domains show the densest new output; LADA and Closed-Loop remain low-volume (expected).

---

## Gap Analysis Summary

Top under-researched intersections (Gap Score 100, BRONZE validation — single source, needs expert confirmation):

1. **Beta Cell Regen × Health Equity** (0 joint pubs)
2. **Insulin Resistance × Islet Transplant** (1)
3. **Islet Transplant × Drug Repurposing** (0)
4. **Islet Transplant × Health Equity** (0)
5. **Gene Therapy × LADA** (0)

**Alignment with our Tier 1 contribution areas:**
- **Islet Transplant × Drug Repurposing** (#3) maps squarely onto Tier 1 area #4 (Drug Repurposing Computational Screening) — repurposing immunosuppressants for islet protection is a concrete, data-accessible computational play. Strong candidate.
- **Health Equity** appears in three of the top five; Tier 1 area #6 (Epidemiological / disparity analysis) supports a synthesis here, though equity-pairings are partly an artifact of the small Health Equity corpus (1,872 pubs).
- The cross-domain **Multi-Omics/Biomarker** PubMed papers (Diabetologia miRNA, NPJ proteomic clocks) reinforce Tier 1 area #1 — live literature is actively populating that intersection right now.

Caveat per Research Doctrine: all gap scores are keyword-based and BRONZE-level; verify each with a direct combined-term PubMed query before acting. The underlying matrix is 50 days old — re-run before drawing new conclusions.

---

## Breaking News (web, last 7 days)

- **ADA 86th Scientific Sessions (New Orleans) closed June 8, 2026** with Phase 3 readouts for retatrutide, orforglipron, CagriSema, and survodutide. ([TechTimes](https://www.techtimes.com/articles/318027/20260608/glp-1-drugs-2026-ada-sessions-close-new-standards-end-single-goal-diabetes-care.htm))
- **Retatrutide (Lilly):** Phase 3 reported ~30% weight loss, approaching bariatric-surgery range; the diabetes-population paper is now in *The Lancet* (PMID 42250575) and in our snapshot. ([Lancet via PubMed](https://pubmed.ncbi.nlm.nih.gov/42250575/))
- **Survodutide (Boehringer/Zealand):** glucagon/GLP-1 dual agonist, ~16.6% placebo-adjusted weight reduction at 76 weeks; holds FDA Fast Track + Breakthrough Therapy. ([DrugDiscoveryNews](https://www.drugdiscoverynews.com/five-drug-approvals-to-watch-in-2026-16982))
- **Orforglipron (Lilly, "Foundayo"):** FDA-approved Apr 1, 2026 for chronic weight management; positive Phase 3 T2D data presented. Oral GLP-1, no food/water restriction. *(Approval predates the 7-day window — context only.)* ([Lilly investor release](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill))
- **Tzield (teplizumab):** Sanofi label expanded Apr 2026 to children as young as one to delay Stage 3 T1D — relevant to the three teplizumab Phase 3 trials in our tracker. ([Sanofi](https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650))

---

## Recommended Actions

1. **Re-run the daily pipeline** — no snapshot since Jun 7. Run `python baseline_clinical_trials.py` and `python baseline_pubmed_alerts.py` to refresh Jun 9 data.
2. **Re-run gap analysis** — `python project1_literature_gap_analysis.py`; the matrix is 50 days old.
3. **Read & log the retatrutide *Lancet* paper** (PMID 42250575) — add to tracker under T2D Novel Therapies / GLP-1; cross-link to NCT06260722 / NCT06297603 (retatrutide Phase 3). Evidence level: SILVER (single peer-reviewed Phase 3 RCT, high-impact journal).
4. **Capture ADA 2026 Phase 3 readouts** in the tracker (retatrutide, orforglipron, CagriSema, survodutide) — these are conference-disclosed; mark BRONZE/SILVER pending full publications.
5. **Review cross-domain biomarker papers** PMID 42251203 (*Diabetologia*, three-miRNA beta-cell signature) and 42251179 (*NPJ Digital Medicine*, proteomic clocks) — both feed Tier 1 Multi-Omics Biomarker Integration.
6. **Scope a Tier-1 computational play** on **Islet Transplant × Drug Repurposing** (gap #3) — strongest alignment between the gap list and our drug-repurposing capability; verify the gap with a direct combined-term PubMed query first.
7. **Populate "Notable Trials to Watch"** in `clinical_trials_summary.md` — currently empty; seed with the Vertex VX-880, Lilly baricitinib, vTv cadisegliatin, and Sanofi teplizumab Phase 3 trials.

---

*Generated by the diabetes-hub-monitor scheduled task. Review run only — no existing files were modified. New claims carry preliminary evidence levels per RESEARCH_DOCTRINE.md and require source verification before use.*
